Comprehensive Genomic Profiling and HRD Testing in Ovarian samples

Join us in this webinar to learn more about assessment of homologous recombination deficiency (HRD) with the Oncomine Comprehensive Assay Plus for research purposes

Live Webinar:  Thursday, 26 October 2023

In this webinar, Elaine Wong-Ho of Thermo Fisher Scientific will present an overview of comprehensive genomic profiling (CGP), its role in clinical research of solid tumors and Genomic Instability Metric (GIM) for HRD Assessment.

Dr. Nicola Normanno of the National Cancer Institute Pascale Foundation will then present a research study of the analytical evaluation of the Ion Torrent™ Oncomine™ Comprehensive Assay Plus for homologous recombination deficiency (HRD) testing. The retrospective evaluation included a cohort of ovarian cancer samples and their corresponding clinical outcomes.

Key Learning Objectives:

1. Understand "How" and "Why" Homologous recombination deficiency (HRD) is being measured currently by leading labs
2. The importance of BRCA to HRD  testing in ovarian cancer
3. How the Genomic Instability Metric (GIM) compares to other orthogonal methods

Register now

For Research Use Only.  Not for use on diagnostic procedures.
©2023 Thermo Fisher Scientific Inc.  All rights reserved.  All trademarks are the property of Thermo Fisher Scientific and its subsidiaries, unless otherwise specified.